诊疗一体化铽放射性核素的制备现状

Current Status of Preparation of Terbium Radionuclides for Theranostic Applications

  • 摘要: 铽(Tb)具有四种可用于核医学的放射性同位素,分别是 149Tb、152Tb、155Tb和161Tb。独特的衰变特性和相同的化学性质使得其可标记相同配体、能够形成诊断治疗核素对从而实现核医学的诊疗一体化,在放射性显像和治疗方面具有较大的应用价值。然而,目前只有161Tb有较成熟的生产方法,即通过反应堆中子辐照富集160Gd靶制备无载体的161Tb;其他Tb放射性核素则面临着生产能力和产量方面的挑战,使得其在核医学中的应用受到限制。本文详细阐述了Tb放射性核素的基本特性和制备路线,希望能为Tb放射性核素的研究及应用提供借鉴。

     

    Abstract: Terbium has four clinically available radionuclides for nuclear medicine applications, 149Tb, 152Tb, 155Tb, and 161Tb. Their unique decay properties and identical chemistry make it possible to prepare radiopharmaceuticals with same ligand, thus enabling the better formation of theranostic radionuclide pairs for better theranostics. They have valuable application in radionuclide imaging and therapeutic applications. However, among the Tb series radionuclides, only 161Tb currently has mass production method and its no carrier-added form was obtained via neutron irradiation of enriched 160Gd targets. Other Tb radionuclides face challenges in capacity and yield, which limit their application in nuclear medicine. This review elaborates on the basic properties, the production routes and the latest research of the Tb series radionuclides, hoping it can provide reference for the research and application of Tb series radionuclides in China.

     

/

返回文章
返回